Study Purpose: This study will test a new tool called the NEO-Match® test to see if it can better predict and diagnose pancreatic cancer during a biopsy. The test uses a special machine, the ARTIDIS ART-1 device, to look at tiny details of the cancer tissue.

What to Expect: If you join, you'll have a regular biopsy or surgery for your pancreatic cancer, plus one extra tissue sample taken for the study. Your normal treatment won't change or be delayed. Researchers will collect information about your health and treatment every 3 months for up to 2 years. The study is safe and won't change how you are treated.

• This study lasts up to 2 years with check-ins every 3 months.
• No new treatments or changes to your current care are involved.
• The study is minimal risk and uses standard medical procedures.

Eligibility: Adults 18+ who need a biopsy for a suspicious pancreatic lesion and can give consent can join. This study might help doctors make better treatment choices for pancreatic cancer in the future.